The Incretin effect and the use of dipeptidyl peptidase IV inhibitors

International Journal of Diabetes in Developing Countries

Volumn 27, Issue 3, 2007, Pages 65-68

  Grant, Paul ^a   Dashora, Umesh ^a  

^a East Sussex Healthcare NHS Trust   (United Kingdom)

Author keywords

Dipeptidyl peptidase IV inhibitors; Glucagon like peptide 1; Incretins; Type 2 diabetes

Indexed keywords

EID: 36249019161     PISSN: 09733930     EISSN: None     Source Type: Journal    
DOI: 10.4103/0973-3930.37038     Document Type: Review

References (18)

1. McIntyre N, Holdsworth CD, Turner DS. New interpretation of oral glucose tolerance. Lancet 1964;2:20-1.
2. Conlon JM, Patterson S, Flatt PR. Major contributions of comparative endocrinology to the development and exploitation of the incretin concept. J Exp Zoolog A Comp Exp Biol 2006;305:781-6.
3. Clark WL. Exenatide: From the Gila monster to you: Exenatide is the first of a new class of drugs known as "incretin mimetics"that can enhance your blood glucose control. Diabetes Self Manag 2006;23:36,39-40.
4. Triplitt C, Chiquette E. Exenatide: From the Gila monster to the pharmacy. J Am Pharm Assoc (2003) 2006;46:44-52.
5. Scheen AJ. Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes. Rev Med Liege 2007;62:217-21.
6. Duffy NA, Green BD, Irwin N, Gault VA, McKillop AM, O'harte FP, et al. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: Nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. Eur J Pharmacol 2007;568:278-86.
7. Pratley RE, Salsali A. Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007;23:919-31.
8. Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3 organic anion transporting polypeptide 4C1 and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007;321:673-83.
9. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43.
10. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556-68.
11. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obest Metab 2007;9:194-205.
12. Kleppinger EL, Helms K. The role of vildagliptin in the management of type 2 diabetes mellitus. Ann Pharmacother 2007;41:824-32.
13. Gallwitz B. Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Bare) 2007;43:13-25.
14. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, et al. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004;53:1326-35.
15. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000;97:6874-9.
16. Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:186-93.
17. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz C), Courreges JP, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10.
18. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycaemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21.